Alprostadil (Caverject/MUSE) Cost in Rhode Island

What Does Alprostadil Actually Cost in Rhode Island Right Now?

The average cash-pay price for brand-name alprostadil across Rhode Island retail pharmacies sits at roughly $600 per month in 2026. This figure applies to both Caverject (intracavernosal injection) and MUSE (urethral suppository) at standard on-demand dosing frequency. Prices vary by pharmacy, quantity dispensed, and whether a generic formulation is available on the shelf.

A single Caverject Impulse kit containing six 20 mcg injections typically lists between $500 and $700 depending on the pharmacy. MUSE suppositories at the 1000 mcg strength run similarly. Generic alprostadil injection vials, where stocked, can bring the per-unit cost down by 15 to 30%, though supply remains inconsistent in the Rhode Island market.

Alprostadil was first FDA-approved for erectile dysfunction in 1995, based on a multicenter trial by Linet and Ogrinc (N=296) published in the New England Journal of Medicine. That study showed that intracavernosal alprostadil produced erections sufficient for intercourse in 87% of office-based tests across dose ranges of 2.5 to 20 mcg [1]. The drug has remained a second-line ED treatment for three decades, prescribed when oral PDE5 inhibitors fail or are contraindicated.

Rhode Island's small geography means pharmacy pricing is relatively uniform compared to larger states. Providence, Warwick, and Cranston pharmacies cluster within $20, 40 of each other for the same NDC. The real cost variation comes from insurance coverage, which differs substantially across plans.

Rhode Island Medicaid Coverage for Alprostadil

Rhode Island Medicaid (managed through the state's Medicaid program and its MCOs, including Neighborhood Health Plan of Rhode Island and UnitedHealthcare Community Plan) covers alprostadil for refractory erectile dysfunction. The key word is "refractory." Prior authorization is required, and the prescriber must document that the patient has tried and failed, or has a documented contraindication to, at least one oral PDE5 inhibitor such as sildenafil or tadalafil.

The prior authorization process typically requires a letter of medical necessity from the prescribing urologist or primary care provider. Documentation should include: the specific PDE5 inhibitors tried, the duration and doses attempted, the clinical reason for failure (lack of efficacy, adverse effects, or contraindication), and the proposed alprostadil formulation and dose. The FDA prescribing information for Caverject specifies a starting dose of 2.5 mcg with dose titration performed in the physician's office [2].

According to the American Urological Association's guidelines on erectile dysfunction, intracavernosal injection therapy is a recommended second-line treatment when PDE5 inhibitors are ineffective [3]. This guideline recommendation strengthens prior authorization requests, because it establishes alprostadil as a standard-of-care option rather than an experimental one.

Approval timelines for RI Medicaid prior authorization range from 24 hours to 14 business days. Urgent requests, particularly for patients with documented psychosocial distress related to untreated ED, may be expedited.

Commercial Insurance Coverage in Rhode Island

Blue Cross Blue Shield of Rhode Island, the state's largest commercial insurer, covers alprostadil on its specialty tier for members whose plans include erectile dysfunction treatment. Copays on the specialty tier typically run $75, $150 per fill. Not all employer-sponsored plans include ED drug coverage; self-insured employer plans operating under ERISA may exclude sexual dysfunction treatments entirely.

UnitedHealthcare and Cigna plans available through HealthSource RI (Rhode Island's ACA marketplace) vary in their formulary placement of alprostadil. Some plans list it as a Tier 3 (preferred brand) medication; others relegate it to Tier 4 or exclude it. Step therapy requirements parallel Medicaid's approach: documentation of PDE5 inhibitor failure is nearly universal across payers.

A 2019 analysis published in the Journal of Sexual Medicine found that insurance coverage for injectable ED therapies declined between 2010 and 2018 across commercial payers nationally, with prior authorization requirements increasing by 34% during that period (Mulhall et al., 2019) [4]. Rhode Island's market mirrors this national trend.

For patients with Medicare Part D in Rhode Island, alprostadil coverage depends on the specific Part D plan. Medicare Part D plans are not required to cover erectile dysfunction drugs under the statutory exclusion in the Social Security Act, though some plans voluntarily include them. Patients should check their plan's formulary on Medicare.gov or contact their plan directly.

Compounded Alprostadil in Rhode Island: Legality and Cost

Compounded alprostadil is legal in Rhode Island through licensed 503A compounding pharmacies. These pharmacies operate under individual patient prescriptions and must comply with both Rhode Island Board of Pharmacy regulations and FDA guidance on 503A compounding. Alprostadil is not on the FDA's "difficult to compound" list and is considered a bulk drug substance that may be compounded for identified individual patients.

The cost advantage is substantial. Compounded alprostadil formulations, including trimix (alprostadil + papaverine + phentolamine) and bimix (papaverine + phentolamine, sometimes with alprostadil), typically cost $50, $150 per multi-dose vial from a 503A pharmacy. A single vial may provide 10, 20 doses depending on the patient's titrated dose, bringing the per-use cost to $5, $15 compared with $80, $120 per use for brand Caverject.

Trimix is the most commonly compounded injectable ED formulation prescribed in Rhode Island. A typical starting concentration is alprostadil 10 mcg/mL + papaverine 30 mg/mL + phentolamine 1 mg/mL. The prescribing clinician specifies the concentration based on the patient's in-office titration results.

Rhode Island does not have state-specific restrictions beyond standard 503A compliance that would limit access to compounded alprostadil. The key legal distinction: 503A pharmacies compound pursuant to individual prescriptions, while 503B outsourcing facilities may compound without patient-specific prescriptions but must register with the FDA. Both pathways are available to Rhode Island residents.

Patients can also obtain compounded alprostadil from out-of-state 503A pharmacies that ship to Rhode Island, provided the pharmacy holds appropriate licensure. Several national compounding pharmacies with non-resident pharmacy licenses in Rhode Island offer mail-order trimix with cold-chain shipping.

Telehealth Prescribing of Alprostadil in Rhode Island

Rhode Island permits telehealth prescribing of alprostadil. The state codified telehealth parity through R.I. Gen. Laws § 27-81 and subsequent regulatory updates, requiring commercial insurers to cover telehealth-delivered services at parity with in-person visits. This means a urologist or men's health provider can evaluate, prescribe, and manage alprostadil therapy via video visit.

One clinical consideration: the FDA label for Caverject recommends that dose titration be performed in a clinician's office with monitoring for prolonged erection (priapism) [2]. The AUA guidelines echo this recommendation. Most telehealth providers who prescribe intracavernosal alprostadil require an initial in-office titration visit, even if follow-up management occurs virtually. Patients in rural areas of Rhode Island (Washington County, parts of Newport County) can access initial titration at urology practices in Providence or Warwick, then transition to telehealth follow-up.

MUSE (urethral suppository) carries fewer titration safety concerns than intracavernosal injection and is sometimes initiated via telehealth without an in-office test dose, though practice patterns vary by provider.

Manufacturer and Generic Savings Programs

Pfizer's patient assistance program covers Caverject for uninsured or underinsured patients who meet income eligibility requirements (typically at or below 200% of the federal poverty level). The application requires income documentation and a signed prescription. Approved patients receive medication at no cost for a defined period, usually 12 months with annual renewal.

For commercially insured patients, Pfizer has periodically offered copay savings cards for Caverject that reduce out-of-pocket costs to $25, $50 per fill. Availability of these programs changes; patients should verify current offers on the manufacturer's website or through their prescriber.

Generic alprostadil injection (manufactured by companies including Endo and Hikma) may be priced 20 to 30% below brand Caverject. A systematic review in the British Journal of Clinical Pharmacology confirmed bioequivalence of generic prostaglandin E1 formulations with brand products [5]. Rhode Island pharmacies may substitute generic alprostadil unless the prescriber writes "brand medically necessary."

Additional savings options for Rhode Island residents include:

GoodRx and RxSaver discount cards, which aggregate negotiated cash prices across pharmacies. These can reduce Caverject costs by 10 to 25% at participating RI pharmacies. Discount cards are not insurance and cannot be combined with insurance copays.

The NeedyMeds database and RxAssist clearinghouse catalog active patient assistance programs and are searchable by drug name. Both are free to access.

How Alprostadil Compares to PDE5 Inhibitors on Cost

The cost differential between alprostadil and oral PDE5 inhibitors in Rhode Island is significant. Generic sildenafil (20 mg tablets, often prescribed off-label at 60 to 100 mg for ED) costs $10, $40 per month at Rhode Island pharmacies. Generic tadalafil runs $15, $60 per month. Brand Viagra and Cialis are more expensive but still typically below alprostadil's price point.

This cost gap explains why all Rhode Island payers require step therapy through PDE5 inhibitors before approving alprostadil. The clinical rationale aligns with the economic one: a meta-analysis of 82 trials (N=47,626) in the Cochrane Database of Systematic Reviews found that PDE5 inhibitors produce satisfactory erections in 65 to 70% of men with ED [6]. Alprostadil is reserved for the 30 to 35% who do not respond adequately.

For the subset of patients who need alprostadil, cost optimization typically follows a predictable sequence: try generic intracavernosal alprostadil first, escalate to compounded trimix if the dose requirement exceeds 20 mcg (trimix reduces the alprostadil dose needed), and reserve brand Caverject or MUSE for patients who prefer the convenience of prefilled devices.

Safety Considerations That Affect Cost Planning

Alprostadil's safety profile directly influences total cost of care. Penile pain is the most common adverse effect, occurring in approximately 37% of patients in clinical trials (Linet & Ogrinc, 1996) [1]. Priapism (erection lasting longer than 4 hours) occurs in 1 to 3% of patients and constitutes a urological emergency that can generate emergency department costs of $1,000, $5,000 depending on the intervention required.

Dr. Arthur Burnett, professor of urology at Johns Hopkins and lead author of the AUA erectile dysfunction guidelines, has stated: "Proper in-office titration to the minimum effective dose is the single most important step in preventing priapism with intracavernosal therapy" [3].

The Endocrine Society's clinical practice guideline on testosterone therapy notes that erectile dysfunction in hypogonadal men should be treated with testosterone replacement first, with alprostadil reserved for patients whose ED persists after testosterone normalization [7]. This sequencing matters for cost planning because testosterone therapy (if indicated) may resolve the ED without alprostadil ever being needed.

Penile fibrosis, reported in 2 to 8% of long-term users, may require treatment discontinuation and can lead to additional diagnostic costs (penile ultrasound, $200, $500). Patients using alprostadil should plan for periodic urological follow-up, typically every 6 to 12 months, adding $150, $300 per visit (before insurance) to the annual cost of therapy.

The AUA recommends that patients self-inject no more than three times per week, with at least 24 hours between doses [3]. This frequency ceiling effectively caps the monthly medication cost, though patients using the maximum frequency will be at the higher end of cost estimates.